Emerging Markets Slowdown Trips Up Lilly’s 2014 Revenue Estimates
This article was originally published in PharmAsia News
Executive Summary
Lilly says emerging markets represent “clear and significant opportunity” despite recent difficulties.
You may also be interested in...
Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands
MUMBAI - Explosive growth in India's anti-diabetes medicines market is turning arch rivals into allies. The latest example is of Eli Lilly & Co. combining forces with German giant Boehringer Ingelheim GmbH.
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.